VERTEX PHARMACEUTICALS INC / MA Research And Development Expense

Quick Answer

VERTEX PHARMACEUTICALS INC / MA reported Research And Development Expense of $3.05 billion for the year ending 2021.

  • VERTEX PHARMACEUTICALS INC / MA showed an increase of +66.8% in Research And Development Expense from 2020 to 2021.
  • This data is from VERTEX PHARMACEUTICALS INC / MA's annual report (Form 10-K), filed with the SEC on February 9, 2022.
  • XBRL data for this metric is available from 2008 to 2021 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 14 years of available data (2008 to 2021), VERTEX PHARMACEUTICALS INC / MA's Research And Development Expense has grown by 490.3%.
  • Historical annual values: Fiscal year 2021: $3.05 billion | Fiscal year 2020: $1.83 billion | Fiscal year 2019: $1.75 billion | Fiscal year 2018: $1.42 billion | Fiscal year 2017: $1.32 billion | Fiscal year 2016: $1.05 billion | Fiscal year 2015: $995.92 million | Fiscal year 2014: $855.51 million | Fiscal year 2013: $882.10 million | Fiscal year 2012: $765.91 million | Fiscal year 2011: $707.71 million | Fiscal year 2010: $637.42 million | Fiscal year 2009: $550.27 million | Fiscal year 2008: $516.91 million.
  • Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: